Findings from home-based HIV testing and facilitated linkage after scale-up of test and treat in rural South Africa: young people still missing.


Journal

HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392

Informations de publication

Date de publication:
11 2019
Historique:
accepted: 05 07 2019
pubmed: 28 8 2019
medline: 29 5 2020
entrez: 28 8 2019
Statut: ppublish

Résumé

The aim of the study was to estimate rates of linkage to HIV care and antiretroviral treatment (ART) initiation after the introduction of home-based HIV counselling and testing (HBHCT) and telephone-facilitated support for linkage in rural South Africa. A population-based prospective cohort study was carried out in KwaZulu Natal, South Africa. All residents aged ≥ 15 years were eligible for HBHCT. Those who tested positive and were not in care were referred for ART at one of 11 public-sector clinics. Individuals who did not attend the clinic within 2 weeks were sent a short message service (SMS) reminder; those who had not attended after a further 2 weeks were telephoned by a nurse counsellor, to discuss concerns and encourage linkage. Kaplan-Meier methods were used to estimate the proportion of newly diagnosed individuals linking to care and initiating ART. Among 38 827 individuals visited, 26% accepted HBHCT. Uptake was higher in women than in men (30% versus 20%, respectively), but similar in people aged < 30 years and ≥ 30 years (28% versus 26%, respectively). A total of 784 (8%) tested HIV positive, of whom 427 (54%) were newly diagnosed. Within 6 months, 31% of women and 18% of men < 30 years old had linked to care, and 29% and 16%, respectively, had started ART. Among those ≥ 30 years, 41% of women and 38% of men had linked to care within 6 months, and 41% and 35%, respectively, had started ART. Despite facilitated linkage, rates of timely linkage to care and ART initiation after HBHCT were very low, particularly among young men. Innovations are needed to provide effective HIV care and prevention interventions to young people, and thus maximize the benefits of universal test and treat.

Identifiants

pubmed: 31454139
doi: 10.1111/hiv.12787
pmc: PMC6788950
mid: NIHMS1044104
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

704-708

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI124718
Pays : United States
Organisme : Wellcome Trust
ID : 201433
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : US National Institutes of Health
ID : P30 30AI060354
Pays : International
Organisme : Wellcome Trust
ID : 082384/Z/07/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K012126/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : K23 MH099916
Pays : United States
Organisme : UK Medical Research Council
ID : MR/K012126/1
Pays : International
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States

Informations de copyright

© 2019 British HIV Association.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet HIV. 2018 Mar;5(3):e116-e125
pubmed: 29199100
AIDS Care. 2017 Oct;29(10):1198-1204
pubmed: 28325077
AIDS. 2017 Feb 20;31(4):545-552
pubmed: 28121668
JAMA. 2017 Jun 6;317(21):2196-2206
pubmed: 28586888
PLoS One. 2018 Oct 16;13(10):e0203193
pubmed: 30325932
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
Trop Med Int Health. 2017 Jul;22(7):807-821
pubmed: 28449385
AIDS. 2012 Oct 23;26(16):2059-67
pubmed: 22781227
AIDS Behav. 2019 Apr;23(4):929-946
pubmed: 30415432
J Int AIDS Soc. 2012 Dec 31;15(2):18020
pubmed: 23336700
Int J Epidemiol. 2008 Oct;37(5):956-62
pubmed: 17998242

Auteurs

K J Baisley (KJ)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Africa Health Research Institute, KwaZulu-Natal, South Africa.

J Seeley (J)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Africa Health Research Institute, KwaZulu-Natal, South Africa.

M J Siedner (MJ)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
Harvard School of Public Health, Boston, MA, USA.

K Koole (K)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Africa Health Research Institute, KwaZulu-Natal, South Africa.

P Matthews (P)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
Division of Infection and Immunity, University College London, London, UK.

F Tanser (F)

Africa Health Research Institute, KwaZulu-Natal, South Africa.

T Bärnighausen (T)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
Harvard School of Public Health, Boston, MA, USA.
University of Heidelberg, Heidelberg, Germany.

T Smit (T)

Africa Health Research Institute, KwaZulu-Natal, South Africa.

D Gareta (D)

Africa Health Research Institute, KwaZulu-Natal, South Africa.

S Dlamini (S)

Africa Health Research Institute, KwaZulu-Natal, South Africa.

K Herbst (K)

Africa Health Research Institute, KwaZulu-Natal, South Africa.

Yapa Hm (Y)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
The Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia.

Iwuji Cc (I)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK.

Kim Hy (K)

Africa Health Research Institute, KwaZulu-Natal, South Africa.

Pillay D (P)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
Division of Infection and Immunity, University College London, London, UK.

Shahmanesh M (S)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
Institute for Global Health, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH